IVVD Stock Overview
Invivyd, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Invivyd, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.44 |
| 52 Week High | US$4.90 |
| 52 Week Low | US$1.03 |
| Beta | 0 |
| 1 Month Change | 30.45% |
| 3 Month Change | -17.53% |
| 1 Year Change | -51.85% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -93.13% |
Recent News & Updates
Will Invivyd (NASDAQ:IVVD) Spend Its Cash Wisely?
Mar 19
Is Invivyd (NASDAQ:IVVD) In A Good Position To Deliver On Growth Plans?
Nov 19Recent updates
Will Invivyd (NASDAQ:IVVD) Spend Its Cash Wisely?
Mar 19Is Invivyd (NASDAQ:IVVD) In A Good Position To Deliver On Growth Plans?
Nov 19Invivyd appoints interim CFO, makes headcount changes
Oct 13Adagio Therapeutics changes name to Invivyd, generates COVID-19 antibodies
Sep 12Adagio Therapeutics GAAP EPS of -$0.47
Aug 15We're Keeping An Eye On Adagio Therapeutics' (NASDAQ:ADGI) Cash Burn Rate
Jul 30Adagio names David Hering as permanent CEO and Director
Jul 05Adagio's Round Trip
Mar 02We're Interested To See How Adagio Therapeutics (NASDAQ:ADGI) Uses Its Cash Hoard To Grow
Feb 19Adagio: A COVID-19 Play With Big Potential On Possible Treatment And Prevention
Feb 16Adagio Therapeutics: The Market Is Too Crowded For Its Lead Drug Candidate
Nov 29Shareholder Returns
| IVVD | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.1% | -2.7% | 0.3% |
| 1Y | -51.8% | 8.5% | -0.7% |
Return vs Industry: IVVD underperformed the US Biotechs industry which returned 8.5% over the past year.
Return vs Market: IVVD underperformed the US Market which returned -0.7% over the past year.
Price Volatility
| IVVD volatility | |
|---|---|
| IVVD Average Weekly Movement | 14.8% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IVVD is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: IVVD's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 85 | David Hering | https://invivyd.com |
Invivyd, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company’s lead product candidate is adintrevimab, a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease, as well as developing monoclonal antibody candidates, including VYD222 and VYD224, which provides neutralizing protection against SARS-CoV-2. It also has discovery stage candidates for the prevention of seasonal influenza.
Invivyd, Inc. Fundamentals Summary
| IVVD fundamental statistics | |
|---|---|
| Market Cap | US$157.11m |
| Earnings (TTM) | -US$175.97m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.9x
P/E RatioIs IVVD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IVVD income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | -US$890.00k |
| Gross Profit | US$890.00k |
| Other Expenses | US$176.86m |
| Earnings | -US$175.97m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.61 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did IVVD perform over the long term?
See historical performance and comparison